Literature DB >> 30546621

Pulse-spray catheter-directed thrombolysis with urokinase and argatroban for thrombo-occlusion of an inferior vena cava filter due to heparin-induced thrombocytopenia with thrombosis.

Yoshito Ogihara1, Norikazu Yamada1, Akimasa Matsuda1, Satoshi Ota1, Masaaki Ito1.   

Abstract

A 50-year-old man developed acute sub-massive pulmonary thromboembolism and proximal deep venous thrombosis. A continuous intravenous infusion of unfractionated heparin (UFH) was started, and an inferior vena cava (IVC) filter was implanted. He developed symptomatic complete obstruction of the filter 6 days after the initiation of UFH, and he was transferred to our hospital. We started pulse-spray catheter-directed thrombolysis (CDT) with urokinase. However, thrombocytopenia occurred 11 days after the initiation of heparin. We suspected heparin-induced thrombocytopenia (HIT) with thrombosis (HITT), and switched from UFH to argatroban. In addition, we continued pulse-spray CDT. As a result, thrombocytopenia improved and thrombolysis was successful without complications of recurrent thromboembolism or bleeding, leading to retrieval of the IVC filter. The antigen assay for HIT was strongly positive, supporting our diagnosis. In patients with suspected HIT it is important to switch from heparin to an alternative anticoagulant as soon as possible, and pulse-spray CDT with urokinase and argatroban as anticoagulant therapy may be effective treatment for thrombo-occlusions of IVC filters in patients with HITT. <Learning objective: Thrombo-occlusion is a serious complication of inferior vena cava filters. Anticoagulant therapy alone is not effective for dissolving thrombo-occlusions of inferior vena cava filters. In patients with heparin-induced thrombocytopenia with thrombosis, pulse-spray catheter-directed thrombolysis with urokinase and argatroban as anticoagulant therapy may be effective treatment for venous thrombo-occlusion.>.

Entities:  

Keywords:  Heparin-induced thrombocytopenia; Pulse-spray catheter-directed thrombolysis; Thrombo-occlusion of inferior vena filter

Year:  2016        PMID: 30546621      PMCID: PMC6280738          DOI: 10.1016/j.jccase.2015.12.004

Source DB:  PubMed          Journal:  J Cardiol Cases        ISSN: 1878-5409


  10 in total

Review 1.  Heparin-induced thrombocytopenia: pathogenesis and management.

Authors:  Theodore E Warkentin
Journal:  Br J Haematol       Date:  2003-05       Impact factor: 6.998

2.  Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosis. A retrospective analysis of 408 patients.

Authors:  Andreas Greinacher; Beate Farner; Hartmut Kroll; Thomas Kohlmann; Theodore E Warkentin; Petra Eichler
Journal:  Thromb Haemost       Date:  2005-07       Impact factor: 5.249

Review 3.  Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Lori-Ann Linkins; Antonio L Dans; Lisa K Moores; Robert Bona; Bruce L Davidson; Sam Schulman; Mark Crowther
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

4.  Heparin-induced thrombocytopenia II-induced critical limb ischaemia treated with urokinase and argatroban.

Authors:  Jan Beyer; Kai Halbritter; Matthias Weise; Johannes Leonhard; Sebastian Schellong
Journal:  Thromb Haemost       Date:  2007-08       Impact factor: 5.249

Review 5.  Complications of inferior vena cava filters.

Authors:  David M Sella; W Andrew Oldenburg
Journal:  Semin Vasc Surg       Date:  2013-03       Impact factor: 1.000

6.  Heparin-induced thrombocytopenia in a glioblastoma multiforme patient with inferior vena cava filter placement for deep venous thrombosis.

Authors:  Naoki Nitta; Satoshi Shitara; Kazuhiko Nozaki
Journal:  Neurol Med Chir (Tokyo)       Date:  2011       Impact factor: 1.742

7.  Pulse-spray pharmacomechanical thrombolysis for proximal deep vein thrombosis.

Authors:  N Yamada; K Ishikura; S Ota; A Tsuji; M Nakamura; M Ito; N Isaka; T Nakano
Journal:  Eur J Vasc Endovasc Surg       Date:  2006-02       Impact factor: 7.069

8.  Long-term outcome after additional catheter-directed thrombolysis versus standard treatment for acute iliofemoral deep vein thrombosis (the CaVenT study): a randomised controlled trial.

Authors:  Tone Enden; Ylva Haig; Nils-Einar Kløw; Carl-Erik Slagsvold; Leiv Sandvik; Waleed Ghanima; Geir Hafsahl; Pål Andre Holme; Lars Olaf Holmen; Anne Mette Njaastad; Gunnar Sandbæk; Per Morten Sandset
Journal:  Lancet       Date:  2011-12-13       Impact factor: 79.321

9.  Transcatheter regional urokinase therapy in the management of inferior vena cava thrombosis.

Authors:  J F Angle; A H Matsumoto; M Al Shammari; K D Hagspiel; D J Spinosa; J E Humphries
Journal:  J Vasc Interv Radiol       Date:  1998 Nov-Dec       Impact factor: 3.464

10.  Transcatheter thrombolytic therapy for symptomatic thrombo-occlusion of inferior vena cava filter.

Authors:  Liang Xiao; Jing Shen; Jia-Jie Tong; Zhe Zhang; Xiao-Lin Mu; Zheng-Jia Yi; Shuo Bai; Ke Xu
Journal:  Exp Ther Med       Date:  2012-11-30       Impact factor: 2.447

  10 in total
  1 in total

1.  Effects of wasp venom on venous thrombosis in rats.

Authors:  Fan-Mao Jin; Mei Wang; Xiu-Mei Wu; Huai Xiao; De-Xiao Wang; Guang-Ming Wang; Cheng-Gui Zhang; Hai-Rong Zhao
Journal:  Iran J Basic Med Sci       Date:  2022-07       Impact factor: 2.532

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.